Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com